A Chinese PARP Inhibitor Just Got a European Home
On July 31, 2026, IMPACT Therapeutics (07630.HK) — a Nanjing-founded biotech listed on the Hong Kong Stock Exchange just two and a half months earlier — announced an exclusive partnership with Pharmanovia, a global specialty pharmaceutical company, covering senaparib, the PARP1/2 inhibitor China's NMPA approved in January 2025. Pharmanovia receives exclusive rights to manufacture, develop, and commercialize senaparib as maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer in 66 countries: all 27 European Union member states, the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and the Middle East and North Africa. The announcement ran on PR Newswire on the same day.
The deal is worth up to EUR 423.5 million in total consideration — an upfront payment, near-term regulatory milestones, commercial milestones tied to sales thresholds, and tiered royalties up to the mid-twenties on net sales. For patients, the more interesting fact is the timeline: a Chinese-discovered ovarian cancer drug is already on the market in China, already reimbursed by the national insurer, and now heading to Europe with an EMA decision expected in the second half of 2026. That sequence — China first, then the world — used to run in the opposite direction.
Why This Story Matters for International Patients
Senaparib in numbers
Senaparib reached patients in China roughly eighteen months before it reaches Europe — and it is not approved in the United States at all. For international patients, that gap is the opportunity: the drug is available, reimbursed-anchored, and prescribed by Chinese oncologists who have now used it in clinical practice for over a year.
What Senaparib Is — and Why PARP Maintenance Matters
Senaparib (IMP4297) is a novel, highly potent PARP1/2 inhibitor developed in-house by IMPACT, which describes a unique molecular structure that gives it strong target selectivity and a wide safety window. PARP inhibitors work by blocking the DNA-repair enzyme that cancer cells with BRCA mutations and homologous-recombination deficiencies rely on to survive platinum damage — forcing the tumor cell to die instead of repair. In ovarian cancer, the clinical logic is well established: after first-line platinum-based chemotherapy, PARP maintenance extends the time before the cancer returns.
That is exactly the niche senaparib fills. China's NMPA approved it in January 2025 as first-line maintenance therapy for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieved a complete or partial response to platinum-based chemotherapy — the standard frontline maintenance position. By December 2025 it was on the National Reimbursement Drug List, meaning Chinese hospitals prescribe it within the national insurance framework. IMPACT says it is one of only three companies worldwide with both a commercial-stage PARP1/2 inhibitor and clinical-stage next-generation PARP1-selective inhibitors, and its EMA marketing authorization application has been under review since August 2025.
What the Pharmanovia Deal Changes
The license is the first step in IMPACT's plan to take its validated treatments outside China — and it signals something larger for the site's core audience. Chinese oncology innovation has moved from copycat generics to original molecules with global licensing value: this site covered the record 76 innovative-drug approvals in 2025, and senaparib is a concrete instance of the same trend. A Western specialty pharma paying up to EUR 423.5 million plus mid-twenties royalties for a Chinese PARP inhibitor is a market-level validation that China-discovered drugs meet European regulatory standards.
For ovarian cancer patients specifically, the practical readout is access. Europeans will gain a new maintenance option once the EMA approves — but patients in Southeast Asia, Central Asia, and the Middle East — the largest inbound groups at Chinese hospitals — can access senaparib in China right now, at prices anchored by the NRDL negotiation, without waiting for approvals in their home countries.
Ovarian Cancer Treatment in China: The Full Pathway
Ovarian cancer care in China follows the international standard pathway: cytoreductive surgery, platinum-based combination chemotherapy, then PARP maintenance for responders. What differs is execution — high-volume surgical teams, short wait times, and the maintenance drug already approved and in use. Chinese gynecologic oncology centers handle some of the largest ovarian cancer caseloads in the world, which matters for a disease where surgical skill at removing all visible disease is the single strongest predictor of survival.
Leading options for international patients include Fudan University Shanghai Cancer Center (a national referral center for gynecologic oncology), Peking Union Medical College Hospital in Beijing, and Sun Yat-sen University Cancer Center in Guangzhou. All three run international patient departments that arrange appointments, English interpretation, and visa invitation letters. For a full picture of how the system works for overseas patients, see our cancer treatment in China guide.
The Cost Question: China vs Singapore, Korea, and the West
PARP maintenance is a long-duration therapy — typically two years or more — so price differences compound quickly. In the United States, list prices for PARP inhibitors run into the hundreds of thousands of dollars per year before insurance. In Singapore and Korea, private-pay oncology drug costs sit well above Chinese hospital prices. China's NRDL negotiation process has driven oncology drug prices down by 60-80 percent versus US list prices on many products, and senaparib's December 2025 NRDL listing anchors the price Chinese hospitals charge — including to self-paying international patients.
The realistic comparison for the site's main audiences: an Indonesian, Vietnamese, Russian, or Middle Eastern ovarian cancer patient weighing China against Singapore, Korea, or India will typically find the Chinese pathway cheaper on the drug component and comparable on surgical and hospital costs — with the additional advantage that the specific maintenance drug is already commercially available. Our cancer treatment cost guide breaks down the full cost picture, and the why international patients choose China piece explains the structural reasons behind the price gap.
The China-Specific Extra: Integrated TCM-Western Oncology Support
Chinese cancer centers add a layer Western hospitals rarely offer: integrated Chinese-Western oncology care (中西医结合) alongside the standard protocol. While a patient receives platinum chemotherapy and PARP maintenance, Chinese hospitals routinely add supportive TCM — acupuncture for chemotherapy-induced nausea and peripheral neuropathy, herbal formulas to manage fatigue and appetite loss, and post-surgical recovery protocols. This is not alternative treatment replacing the oncology protocol; it is adjunctive symptom management delivered inside the same hospital, by the same care team.
The evidence base is real: acupuncture for chemotherapy-induced nausea is among the best-documented uses of the therapy in Western clinical research, and Chinese centers have decades of clinical experience combining herbal support with platinum regimens. For international patients the practical benefit is measurable — better tolerance of a long maintenance journey. Our integrated Chinese-Western medicine guide explains how the model works, and the TCM in China guide covers how to book these services.
How International Patients Access Ovarian Cancer Care in China
The access pathway is well established and runs through the hospital's international department:
- Contact the international patient desk at a major cancer center — Fudan Shanghai, PUMC, or Sun Yat-sen — with the patient's pathology report and imaging. The hospital confirms whether the case is treatable and sends a treatment plan and cost estimate.
- Arrange the visa — medical visa invitation letters are standard practice; our visa guide covers the routes, including visa-free entry via Hainan and the 240-hour transit policy.
- Treatment timeline — surgery within days to two weeks of arrival, platinum chemotherapy over the following months, then PARP maintenance, with follow-up monitoring that can be coordinated remotely after the patient returns home.
For patients interested in research options, Chinese cancer centers run active ovarian cancer trials, and international enrollment is possible through the same international departments; our clinical trials guide explains how that process works.
The bottom line: a Chinese-developed PARP inhibitor, already NMPA-approved and NRDL-listed, is about to become a European drug. For international ovarian cancer patients, the window is open now — the same medicine, at China's negotiated prices, with integrated TCM support that no Western center matches. Senaparib's global licensing history is tracked on clinicaltrials.gov and the full license announcement is available on PR Newswire.